Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase IIIb, Single Arm, Multicenter Safety Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT04148911 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04148911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04148911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase IIIb, Single Arm, Multicenter Safety Study of Atezolizumab (Tecentriq) Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
December 10, 2019
Completion date
December 15, 2024
Enrollment
184 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer